

# Geoffrey Masuyer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6954036/publications.pdf>

Version: 2024-02-01

44  
papers

1,770  
citations

279487

23  
h-index

288905

40  
g-index

46  
all docs

46  
docs citations

46  
times ranked

2084  
citing authors

#	ARTICLE	IF	CITATIONS
1	Structural Analysis of Botulinum Neurotoxins Type B and E by Cryo-EM. <i>Toxins</i> , 2022, 14, 14.	1.5	5
2	Small-molecule activation of OGG1 increases oxidative DNA damage repair by gaining a new function. <i>Science</i> , 2022, 376, 1471-1476.	6.0	20
3	Mechanism of Ganglioside Receptor Recognition by Botulinum Neurotoxin Serotype E. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8315.	1.8	5
4	Structural and Biochemical Characterization of Botulinum Neurotoxin Subtype B2 Binding to Its Receptors. <i>Toxins</i> , 2020, 12, 603.	1.5	6
5	Targeting OGG1 arrests cancer cell proliferation by inducing replication stress. <i>Nucleic Acids Research</i> , 2020, 48, 12234-12251.	6.5	29
6	Crystal Structure of Exotoxin A from <i>Aeromonas</i> Pathogenic Species. <i>Toxins</i> , 2020, 12, 397.	1.5	6
7	Characterization of a membrane binding loop leads to engineering botulinum neurotoxin B with improved therapeutic efficacy. <i>PLoS Biology</i> , 2020, 18, e3000618.	2.6	18
8	A neurotoxin that specifically targets <i>Anopheles</i> mosquitoes. <i>Nature Communications</i> , 2019, 10, 2869.	5.8	50
9	Structural basis for the interaction of the chaperone Cbp3 with newly synthesized cytochrome b during mitochondrial respiratory chain assembly. <i>Journal of Biological Chemistry</i> , 2019, 294, 16663-16671.	1.6	6
10	Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models. <i>Science Advances</i> , 2019, 5, eaau7196.	4.7	29
11	Crystal structure of the catalytic domain of the <i>Weissella oryzae</i> botulinum-like toxin. <i>FEBS Letters</i> , 2019, 593, 1403-1410.	1.3	8
12	Botulinum and Tetanus Neurotoxins. <i>Annual Review of Biochemistry</i> , 2019, 88, 811-837.	5.0	140
13	Identification of a Botulinum Neurotoxin-like Toxin in a Commensal Strain of <i>Enterococcus faecium</i> . <i>Cell Host and Microbe</i> , 2018, 23, 169-176.e6.	5.1	127
14	Structural characterisation of the catalytic domain of botulinum neurotoxin X - high activity and unique substrate specificity. <i>Scientific Reports</i> , 2018, 8, 4518.	1.6	30
15	Mechanism of Peptide Binding and Cleavage by the Human Mitochondrial Peptidase Neurolysin. <i>Journal of Molecular Biology</i> , 2018, 430, 348-362.	2.0	29
16	Small-molecule inhibitor of OGG1 suppresses proinflammatory gene expression and inflammation. <i>Science</i> , 2018, 362, 834-839.	6.0	156
17	Crystal Structure of Botulinum Neurotoxin A2 in Complex with the Human Protein Receptor SV2C Reveals Plasticity in Receptor Binding. <i>Toxins</i> , 2018, 10, 153.	1.5	14
18	Glycans Confer Specificity to the Recognition of Ganglioside Receptors by Botulinum Neurotoxin A. <i>Journal of the American Chemical Society</i> , 2017, 139, 218-230.	6.6	50

#	ARTICLE	IF	CITATIONS
19	Identification and characterization of a novel botulinum neurotoxin. <i>Nature Communications</i> , 2017, 8, 14130.	5.8	196
20	The structure of the tetanus toxin reveals pH-mediated domain dynamics. <i>EMBO Reports</i> , 2017, 18, 1306-1317.	2.0	61
21	Crystal structure of a peptidyl dipeptidase K <sub>26</sub> DCP from <i>Actinomycete</i> in complex with its natural inhibitor. <i>FEBS Journal</i> , 2016, 283, 4357-4369.	2.2	6
22	Kinetic and structural characterization of amyloid $\beta$ peptide hydrolysis by human angiotensin $\text{I}$ -converting enzyme. <i>FEBS Journal</i> , 2016, 283, 1060-1076.	2.2	19
23	NUDT15 Hydrolyzes 6-Thio-DeoxyGTP to Mediate the Anticancer Efficacy of 6-Thioguanine. <i>Cancer Research</i> , 2016, 76, 5501-5511.	0.4	96
24	Structural analysis of <i>Clostridium botulinum</i> neurotoxin type D as a platform for the development of targeted secretion inhibitors. <i>Scientific Reports</i> , 2015, 5, 13397.	1.6	12
25	Structural basis of Ac-SDKP hydrolysis by Angiotensin-I converting enzyme. <i>Scientific Reports</i> , 2015, 5, 13742.	1.6	18
26	Structural basis of multivalent galactose $\alpha$ -based dendrimer recognition by human galectin $\beta$ . <i>FEBS Journal</i> , 2015, 282, 372-387.	2.2	13
27	Fragment-based design for the development of N-domain-selective angiotensin-1-converting enzyme inhibitors. <i>Clinical Science</i> , 2014, 126, 305-313.	1.8	36
28	Absence of cell surface expression of human ACE leads to perinatal death. <i>Human Molecular Genetics</i> , 2014, 23, 1479-1491.	1.4	14
29	Engineered Botulinum Neurotoxins as New Therapeutics. <i>Annual Review of Pharmacology and Toxicology</i> , 2014, 54, 27-51.	4.2	55
30	Angiotensin-I converting enzyme (ACE): structure, biological roles, and molecular basis for chloride ion dependence. <i>Biological Chemistry</i> , 2014, 395, 1135-1149.	1.2	43
31	Molecular and Thermodynamic Mechanisms of the Chloride-dependent Human Angiotensin-I-converting Enzyme (ACE). <i>Journal of Biological Chemistry</i> , 2014, 289, 1798-1814.	1.6	29
32	Crystal structures of highly specific phosphinic tripeptide enantiomers in complex with the angiotensin $\text{I}$ -converting enzyme. <i>FEBS Journal</i> , 2014, 281, 943-956.	2.2	27
33	Interkingdom Pharmacology of Angiotensin-I Converting Enzyme Inhibitor Phosphonates Produced by Actinomycetes. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 346-351.	1.3	26
34	Structure Based Drug Design of Angiotensin-I Converting Enzyme Inhibitors. <i>Current Medicinal Chemistry</i> , 2012, 19, 845-855.	1.2	47
35	Structural basis of peptide recognition by the angiotensin $\text{I}$ converting enzyme homologue An $\text{ACE}$ from <i>Drosophila melanogaster</i> . <i>FEBS Journal</i> , 2012, 279, 4525-4534.	2.2	21
36	Molecular recognition and regulation of human angiotensin-I converting enzyme (ACE) activity by natural inhibitory peptides. <i>Scientific Reports</i> , 2012, 2, 717.	1.6	127

#	ARTICLE	IF	CITATIONS
37	Inhibition mechanism of human galectin-7 by a novel galactose-benzylphosphate inhibitor. FEBS Journal, 2012, 279, 193-202.	2.2	18
38	Engineering botulinum neurotoxin domains for activation by toxin light chain. FEBS Journal, 2012, 279, 515-523.	2.2	13
39	Structure and activity of a functional derivative of Clostridium botulinum neurotoxin B. Journal of Structural Biology, 2011, 174, 52-57.	1.3	21
40	Structural characterization of angiotensin-converting enzyme in complex with a selenium analogue of captopril. FEBS Journal, 2011, 278, 3644-3650.	2.2	33
41	Structures of engineered Clostridium botulinum neurotoxin derivatives. Acta Crystallographica Section F: Structural Biology Communications, 2011, 67, 1466-1472.	0.7	9
42	Isolation and pharmacological characterization of AdTx1, a natural peptide displaying specific insurmountable antagonism of the $\alpha_1A$ -adrenoceptor. British Journal of Pharmacology, 2010, 159, 316-325.	2.7	43
43	Identification of a novel snake peptide toxin displaying high affinity and antagonist behaviour for the $\alpha_2$ -adrenoceptors. British Journal of Pharmacology, 2010, 161, 1361-1374.	2.7	36
44	Crystal structure of a catalytically active, non-toxic endopeptidase derivative of Clostridium botulinum toxin A. Biochemical and Biophysical Research Communications, 2009, 381, 50-53.	1.0	23